Flagship Secures Series A Funding to Accelerate Growth in Drug Development and Diagnostics Services

Westminster, CO, July 10, 2018 – Flagship Biosciences has closed a series A round of funding to advance the growth of its computational tissue image analysis technology platform and biomarker-driven drug development and diagnostic services. Since 2009, Flagship’s integrated team of scientists, pathologists, tissue and data analysts, and software engineers has worked with some of […]

Read More

Flagship publishes article on using IHC and digital imaging to improve patient selection for PD-L1 therapy

First NSCLC study using cTA to report IHC data in immuno-oncology Westminster, CO, June 7, 2018 – Flagship is proud to co-author the research paper, PD-L1 immunostaining scoring for non-small cell lung cancer based on immunosurveillance parameters, published June 6, 2018, in PLOS ONE, an open access peer-reviewed journal. The paper is the first Non-Small […]

Read More

Flagship Participates in ASCO Annual Meeting 2018

Download Flagship ASCO booth map Westminster, CO, May 23, 2018 – Flagship Biosciences will participate in the largest annual gathering of oncology professionals and researchers at the ASCO Annual Meeting 2018, June 1 – 5, 2018, in Chicago. Visit us in booth #25115 to learn how Flagship’s cTA® platform can help drive precision decisions for more […]

Read More

Flagship to Present Computational Tissue Analysis Solutions for Advancing Drug Development at AACR Annual Meeting

Download Flagship AACR reference Westminster, CO, April 12, 2018 – Flagship Biosciences’ cTA® and decision support platform will be featured in four scientific poster presentations at the American Association for Cancer Research (AACR) Annual Meeting, April 14-18, 2018, in Chicago. As the leading partner for drug developers investigating tissue-based biomarkers, Flagship applies computational tissue analysis […]

Read More

Flagship Receives Accreditation from College of American Pathologists

Westminster, CO, April 10, 2018 – The Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to Flagship Biosciences, based on results of a recent on-site inspection as part of the CAP’s Accreditation Programs. “CAP accreditation validates Flagship’s commitment and dedication to ensuring the highest quality for our clients and patients,” says […]

Read More

Flagship Biosciences ActionAnalysis Solutions Accelerate Drug Development

Ready-to-use and custom image analysis meets current and future development needs Westminster, CO, February 12, 2018 – Flagship Biosciences is adding to its menu of ready-to-use image solutions with the introduction of ActionAnalysisTM. As the most experienced, integrated clinical laboratory, Flagship’s ActionAnalysis solutions help drug developers rapidly evaluate existing targets to define a biomarker-driven path […]

Read More

Flagship supports Summit Therapeutics advancement of DMD therapies

January 26, 2018 – Flagship is proud to partner with Summit Therapeutics in its efforts to advance therapies for patients with Duchenne Muscular Dystrophy (DMD). Summit Therapeutics issued a news release disclosing the interim results from its DMD phase II clinical trial, PhaseOut DMD. The endpoints reported by Flagship for these efforts are the first […]

Read More

Flagship Biosciences ActionAssays Deliver Actionable Data to Drive Immuno-Oncology Decisions

Comprehensive catalog of assays advance biomarker programs Westminster, CO, January 16, 2018 – Flagship Biosciences has introduced a new menu of services to help drug developers more confidently define their path to success. ActionAssaysTM is a comprehensive catalog of brightfield immunohistochemistry (IHC) assays that provide actionable data to define and advance biomarker programs. ActionAssays includes […]

Read More

Flagship Biosciences Presents PD-L1 Scoring Method at SITC 2017 that could Eliminate Reliance on Complex Multiplex IHC Assays

Novel cTA™-based morphometric biomarker interpretation approach quantifies immune cells in tumor tissues and has potential to revolutionize PD-L1 diagnostics landscape National Harbor, MD – November 11th 2017 – Flagship Biosciences, Inc., the leading developer of quantitative tissue biomarker interpretations for clinical development of tissue-based diagnostics to drive clinical decisions for industry partners, presented data today […]

Read More

Flagship Biosciences, Inc. Receives Prestigious Best Research Award for Poster on PD-L1 Harmonization at Pathology Visions 2017 Conference

Westminster, CO, Oct. 4, 2017 – Flagship Biosciences was honored to receive the award for Best Poster in the Research Category at the Pathology Visions 2017 annual conference in San Diego, CA for their poster on Evaluating Image Analysis Approaches Toward “Harmonization” of PD-L1 Assays. The poster describes how Flagships’ proprietary Computational Tissue Analysis (cTA™) […]

Read More